Skip to main content
589 search results for:

Psoriatic arthritis 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 04-06-2022 | EULAR 2022 | Conference coverage | Article

    Bimekizumab beneficial for psoriatic arthritis in phase 3 trials

    Bimekizumab has shown positive efficacy and safety results in the BE COMPLETE and BE OPTIMAL phase 3 psoriatic arthritis trials.

  2. 19-05-2022 | Psoriatic arthritis | News | Article

    Residual disease burden highlighted in people with psoriatic arthritis

    Some people with psoriatic arthritis continue to experience a range of residual symptoms despite meeting stringent treatment targets, indicates a systematic review of real-world data.

  3. 17-06-2022 | Psoriasis | Adis Journal Club | Article
    Rheumatology and Therapy

    Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study

    Authors: Silvia Scriffignano, Fabio Massimo Perrotta, Mario di Marino, Francesco Ciccia & Ennio Lubrano Abstract Objectives To stratify psoriatic arthritis (PsA) patients based on psoriasis (PsO) onset age: early onset psoriasis (EOP) vs. late onset psoriasis (LOP), and to assess if there are differences in disease characteristics, activity/function/impact of the disease, and comorbidity indices.

  4. 17-05-2022 | Psoriasis | Adis Journal Club | Article
    Rheumatology and Therapy

    Exploring the Association Between History of Psoriasis (PSO) and Disease Activity in Patients with Psoriatic Arthritis (PsA)

    DOI [Teaser] Key Summary Points History of psoriasis (PSO), either personal or family history, is an important factor in the diagnosis of psoriatic arthritis (PsA).

  5. 26-01-2022 | Psoriatic arthritis | News | Article
    approvalsWatch

    FDA approves risankizumab for psoriatic arthritis

    medwireNews : The indication for risankizumab has been expanded  to include psoriatic arthritis (PsA) in the USA.

  6. 18-12-2020 | Upadacitinib | News | Article
    approvalsWatch

    EMA gives nod to upadacitinib for psoriatic arthritis, ankylosing spondylitis

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended that the indication for upadacitinib should be expanded to include psoriatic arthritis (PsA) and ankylosing spondylitis (AS).

  7. 19-01-2022 | Psoriatic arthritis | News | Article

    Comorbidities may contribute to link between psoriatic arthritis and VTE risk

    People with psoriatic arthritis have an increased risk for venous thromboembolism relative to the general population, and this association is likely to be related to underlying comorbidities, research suggests.

  8. 06-12-2021 | Infection | Adis Journal Club | Article
    Rheumatology and Therapy

    Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment

    We evaluated clinical study data relating to HZ management in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) receiving tofacitinib.

  9. 20-12-2021 | Psoriatic arthritis | News | Article
    approvalsWatch

    FDA approves upadacitinib for selected psoriatic arthritis patients

    medwireNews : The US FDA has approved upadacitinib for the treatment of adult patients with active psoriatic arthritis (PsA) and an inadequate response or intolerance to at least one tumor necrosis factor (TNF) inhibitor.

  10. 11-11-2020 | ACR 2020 | Conference coverage | Article

    ​​​​​​​Early findings encouraging for deucravacitinib in psoriatic arthritis

    Deucravacitinib, a novel selective tyrosine kinase 2 inhibitor, may be a promising treatment option for patients with psoriatic arthritis, suggest phase 2 data presented in a poster at the ACR Convergence 2020 virtual meeting.

  11. 07-11-2021 | ACR 2021 | Conference coverage | Article

    Brepocitinib shows promise in psoriatic arthritis

    The oral small-molecule tyrosine kinase 2/JAK1 inhibitor brepocitinib improves several measures of disease activity, relative to placebo, without excessive toxicity in people with psoriatic arthritis, phase 2b study findings indicate.

  12. 19-11-2021 | Psoriatic arthritis | Adis Journal Club | Article
    Rheumatology and Therapy

    Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice

    Authors: Sneha Patel & Anand Kumthekar Abstract Psoriatic arthritis (PsA) is associated with a higher burden of co-morbidities such as obesity, cardiovascular disease, non-alcoholic fatty liver disease, inflammatory eye disease, inflammatory bowel disease, skin cancer and depression compared to the general population.

  13. 14-09-2021 | Psoriatic arthritis | Adis Journal Club | Article
    Rheumatology and Therapy

    Differentiating Psoriatic Arthritis from Osteoarthritis and Rheumatoid Arthritis: A Narrative Review and Guide for Advanced Practice Providers

    Lydon  Abstract Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects multiple organ systems and is characterized by skin and joint manifestations.

  14. 04-03-2021 | Psoriatic arthritis | Adis Journal Club | Article
    Drugs

    Secukinumab: A Review in Psoriatic Arthritis

    Blair Abstract Secukinumab (Cosentyx®) is a fully human monoclonal antibody that selectively targets interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriatic arthritis (PsA).

  15. 20-07-2021 | Psoriatic arthritis | News | Article

    Guselkumab may reduce axial symptoms in psoriatic arthritis

    Guselkumab improves axial symptoms relative to placebo in people with axial psoriatic arthritis and radiographic evidence of sacroiliitis, shows a post-hoc analysis of the DISCOVER-1 and DISCOVER-2 studies.

  16. 03-06-2021 | Adis Journal Club | Article
    Drugs & Therapy Perspectives

    Guselkumab in psoriatic arthritis: a profile of its use

    Guselkumab (TREMFYA®) treats psoriatic arthritis via a novel mechanism of action.

  17. 01-10-2021 | Psoriatic arthritis | Adis Journal Club | Article
    Rheumatology and Therapy

    Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis

    Authors: Alen Zabotti, Orazio De Lucia, Garifallia Sakellariou, Alberto Batticciotto, Gilberto Cincinelli, Ivan Giovannini, Luca Idolazzi, Gabriella Maioli, Ilaria Tinazzi, Daniel Aletaha, Salvatore De Vita, Antonio Marchesoni, Josef Smolen, Annamaria Iagnocco, Dennis McGonagle & Roberto Cap Abstract Background Agreement on how to identify psoriasis (PsO) patients at risk of developing psoriatic arthritis (PsA) is lacking.

  18. 28-06-2021 | Psoriatic arthritis | News | Article

    Real-world data support TNF inhibitor co-medication strategy in psoriatic arthritis

    Co-medication with methotrexate may improve psoriatic arthritis remission rates for people initiating the TNF inhibitors adalimumab or infliximab, but not etanercept, show data from a large, observational study in Europe.

  19. 20-07-2021 | Psoriatic arthritis | Article

    A summary of the safety data from the phase 3 trials of upadacitinib in psoriatic arthritis

    Author : Claire Barnard With upadacitinib now approved for psoriatic arthritis (PsA) in  Europe  and under consideration by the US FDA, we round up the key safety data on the Janus kinase (JAK)-1 selective inhibitor from the phase 3 studies, SELECT-PsA 1 and SELECT-PsA 2 .

  20. 28-04-2021 | BSR 2021 | Conference coverage | Article

    PASDAS best reflects disease activity, treatment response in psoriatic arthritis

    A comparison of different composite measures suggests that PASDAS has the strongest ability to predict disease activity and treatment response in patients with oligoarticular or polyarticular psoriatic arthritis.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.